Merkel Cell Carcinoma Market is Segmented By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By Diagnosis ....
Market Size in USD
CAGR4.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 4.1% |
Market Concentration | High |
Major Players | Merck, Incyte Corporation, Kartos Therapeutics, Inc., Bristol-Myers Squibb, Amgen Inc. |
The Global Merkel Cell Carcinoma Market is estimated to be valued at USD 2.51 Bn in 2024 and is expected to reach USD 3.38 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031. Merkel cell carcinoma is a rare form of skin cancer that is believed to be caused by the Merkel cell polyomavirus. Increasing awareness regarding early diagnosis and treatment of skin cancer is expected to drive the market during the forecast period.
The market is anticipated to experience steady growth owing to factors such as rising healthcare spending across developed countries, increasing R&D investments for development of novel therapies, and growing geriatric population who are prone to developing the condition. Furthermore, improving reimbursement policies and introduction of combination therapies have opened new avenues for market participants in the global Merkel cell carcinoma market.